Midostaurin Producers and Midostaurin Market Trend

Midostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.

The global Midostaurin market size was USD 60 million in 2017, growing to USD 291 million in 2022, with a CAGR of 37.1% from 2017 to 2022. The global Midostaurin market size is expected to reach USD 342 million in 2027, with a CAGR of 3.3% from 2022 to 2027.

Figure 2017-2027 Global Midostaurin Market Size (Million USD) and CAGR

The global Midostaurin market is dominated by Novartis holding 100% of the market share.

Currently, Europe is the largest Midostaurin consumption region accounting for 63%, followed by comparable consumption in North America market accounting for 32%.